Learn More
AIMS To assess the antitumour activity, safety, pharmacokinetics and pharmacodynamics of continuous daily sunitinib dosing in patients with imatinib-resistant/intolerant gastrointestinal stromal tumour (GIST) and to assess morning dosing versus evening dosing. PATIENTS AND METHODS In this open-label phase II study, patients were randomised to receive(More)
BACKGROUND The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international consensus meeting were to describe the optimal management procedures for patients with GIST in localized and advanced stages, as well as research issues for the future. MATERIALS AND METHODS A panel of(More)
BACKGROUND Patients with advanced solid tumors may be included in phase I clinical trials. In such studies, the benefit expected is generally lower than the likelihood of toxicity and may even be non-existent if the patient's life expectancy is too short. This study was performed to identify prognostic variables for toxicity and survival in patients who(More)
BACKGROUND Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue. The annual incidence of primary breast sarcoma is low and has been estimated at 45 new cases per 10 million women. These tumours are at high risk of recurrence and are known to have poor prognosis.(More)
Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the(More)
10005 Background: The mTOR signaling pathway is activated in most sarcomas. R, an oral mTOR inhibitor, demonstrated activity in phase I-II trials in advanced sarcomas following failure of prior CT. METHODS This trial is an international, double-blind study randomized 1:1 between R (40 mg orally for 5 days/week) vs. placebo (P) as maintenance therapy in(More)
10054 Background: We previously demonstrated that imatinib mesylate (IM) must not be interrupted after 1, 3 and 5 years in responding patients (pts). The impact of treatment interruption on the emergence of resistance to IM or on overall survival (OS) can not be established in this study. However, the tumor volume of residual lesions at the time of IM(More)
10015 Background: We previously demonstrated that interruption of IM treatment after 1, 3, and 5 yrs in responding patients (pts) with advanced GIST are associated with rapid relapse. The impact of IM interruption on secondary resistance and overall survival (OS) with longer-term follow-up was unclear. METHODS This prospective multicenter BFR14 study was(More)
PURPOSE Patients with metastatic or locally advanced, unresectable soft tissue sarcoma (ASTS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDCT) with hematopoietic stem-cell support in this disease is not established. PATIENTS AND METHODS Between 1988 and 1994, 30 patients with(More)
10048 Background: The aim of this work was to characterize patient (pts) characteristics and the mutational status of GIST who benefit the most from IM in term of prolonged response and overall survival. METHODS Among the 434 pts included between June 2002 to July 2009 in the prospective multicentric BFR14 trial, we selected the 236 pts having started IM(More)